Veille Pharma
20.6K views | +0 today
Veille Pharma
Chargé d'affaires chez Patientsworld. Mes posts n'engagent que moi.
Your new post is loading...
Your new post is loading...
Scooped by Alexandre DUBOIS
Scoop.it!

Merck Serono et Ono Pharmaceutical signent deux accords dans les domaines de la sclérose en plaques et de l’oncologie

Merck Serono et Ono Pharmaceutical signent deux accords dans les domaines de la sclérose en plaques et de l’oncologie | Veille Pharma | Scoop.it

Merck Serono, la division biopharmaceutique de Merck KGaA a annoncé aujourd'hui la signature de deux accords distincts avec le japonais Ono Pharmaceutical pour renforcer ses activités dans les domaines de la sclérose en plaques et de l'oncologie.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Sclérose en plaques : la pilule de l'espoir

Un nouveau traitement contre la sclérose en plaque sera mis en vente en France d'ici 2012. Cette pilule représentera 'un énorme progrès pour les malades' informe l'équipe marseillaise qui a participé à son développement.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Biogen Idec et Abbott : résultats positifs pour le Daclizumab HYP contre la sclérose en plaques rémittente

Biogen Idec et Abbott : résultats positifs pour le Daclizumab HYP contre la sclérose en plaques rémittente | Veille Pharma | Scoop.it

Biogen Idec et Abbott annoncent aujourd’hui d’excellents résultats pour l’étude SELECT, un essai clinique mondial d’homologation de phase 2b conçu pour évaluer sur une période d’un an le composé expérimental DAC HYP (daclizumab high-yield process) chez les personnes atteintes de sclérose en plaques rémittente.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Another Blow for Simvastatin Add-on in Multiple Sclerosis

August 31, 2011 — Results from the SIMCOMBIN trial, the largest to date, found no benefit of simvastatin added to interferon in relapsing-remitting multiple sclerosis (MS).

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Rebif sales lift Merck Serono's second-quarter revenue 2 percent | FirstWord Pharma

Rebif sales lift Merck Serono's second-quarter revenue 2 percent | FirstWord Pharma | Veille Pharma | Scoop.it
Second-quarter sales in Merck KGaA's drug unit Merck Serono increased 2 percent to 1.5 billion euros, boosted by revenue from Rebif.
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial : The Lancet Neurology

Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to establish whether add-on of simvastatin, a statin with anti-inflammatory properties, improves this efficacy
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Biogen's MS drug in question - Investors.com

Biogen's MS drug in question - Investors.com | Veille Pharma | Scoop.it
Twelve more cases of a rare brain infection occurred in multiple-sclerosis patients taking the biotech's drug Tysabri, which it sells with Elan (ELN), bringing the number of affected patients to 145.
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Lemtrada Better At Preventing MS Relapses Than Rebif, But Not At Reducing Disability Risk

Lemtrada Better At Preventing MS Relapses Than Rebif, But Not At Reducing Disability Risk | Veille Pharma | Scoop.it
Although Lemtrada (alemtuzumab) was found to be more effective in preventing MS relapses than the older drug - Rebif - it did not prevent multiple sclerosis (MS) from becoming disabling in a late-...
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Merck Acquires Rights to Multiple Sclerosis Drug

Merck Acquires Rights to Multiple Sclerosis Drug | Veille Pharma | Scoop.it

Merck KGaA has acquired worldwide exclusive rights to PI-2301, an experimental drug for multiple sclerosis, previously developed by Peptimmune Inc.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Biogen Idec: résultats liés à la sclérose en plaques.

Biogen Idec: résultats liés à la sclérose en plaques. | Veille Pharma | Scoop.it

(CercleFinance.com) - Biogen Idec et Abbott annoncent les résultats pour le premier essai d'homologation du Daclizumab HYP contre la sclérose en plaques rémittente, qualifiés "d'excellents".

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Medical News: Botox Okayed for Some Types of Overactive Bladder

Medical News: Botox Okayed for Some Types of Overactive Bladder | Veille Pharma | Scoop.it

The FDA has approved botulinum toxin type A (Botox) for treating bladder overactivity resulting from spinal cord injury or multiple sclerosis.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Teva's second-quarter profit drops despite record Copaxone sales | FirstWord Pharma

Teva's second-quarter profit drops despite record Copaxone sales | FirstWord Pharma | Veille Pharma | Scoop.it
Teva reported Wednesday that net income for the second quarter fell to $576 million from $797 million a year earlier, as the company was hit by $221 million in legal charges. According to the drugmaker, the charges relate to recent patent settlement agreements in the US over generic versions of Novartis' Lotrel and Pfizer's Neurontin.
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Elan's second-quarter loss narrows as Tysabri sales grow | FirstWord Pharma

Elan's second-quarter loss narrows as Tysabri sales grow | FirstWord Pharma | Veille Pharma | Scoop.it
Elan reported Wednesday a smaller second-quarter loss of $47.1 million, compared to the net deficit a year ago of $217.9 million.
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Conditional approval in EU for Fampyra

Conditional approval in EU for Fampyra | Veille Pharma | Scoop.it
Biogen Idec Inc. said it received conditional approval from the European Commission for Fampyra to improve walking in adult patients with multiple sclerosis or MS who have walking disability. Fampyra is the first treatment that addresses this unmet medical need with demonstrated efficacy in people with all types of MS.
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Oral fingolimod (Gilenya) in relapsing MS: impact on health-related quality of life in a phase II study

Oral fingolimod (Gilenya) in relapsing MS: impact on health-related quality of life in a phase II study | Veille Pharma | Scoop.it
Gilenya (fingolimod) page with information on Gilenya (fingolimod) and Multiple Sclerosis Research in the MS Research News section of the Multiple Sclerosis Resource Centre (MSRC) website.
more...
No comment yet.